Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.
- The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.
- The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells.
- “Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morrison, Chief Executive Officer of Crossbow.
- Working with MD Anderson’s ORBIT platform, a core component of the institution’s Therapeutics Discovery division , Dr. Molldrem led the development of a TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for the development of off-the-shelf cancer immunotherapies.